Alan Barona

Featured in: Favicon

theprint.in Favicon

streetinsider.com Favicon

newsnationnow.com Favicon

westlaw.com Favicon

insideretail.asia Favicon

newsbeezer.com Favicon

todayschronic.com Favicon

thewealthadvisor.com Favicon

conservativeangle.com Favicon

internetretailing.com.au + 2 more

Articles

Apollo's Aspen Insurance raises $397.5 million in US IPO

1 week ago | today.westlaw.com | Prakhar Srivastava |Chandni Shah |Alan Barona

(Reuters) -Aspen Insurance priced its New York initial public offering within its marketed range on Wednesday, raising $397.5 million for the Bermuda-based specialty insurer.
US FDA approves J&J's immune disorder drug

2 weeks ago | today.westlaw.com | Mariam Sunny |Alan Barona |Leroy Leo |Christy Santhosh

(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's drug to treat a type of muscle-weakening disorder, which is expected to bring in blockbuster revenues and drive growth. J&J had acquired the drug, to be sold...
Sabre to cut debt with $1.1 billion sale of hospitality software to TPG, shares jump

2 weeks ago | today.westlaw.com | Alan Barona |Leroy Leo |Aatreyee Dasgupta |Aishwarya Jain

(Reuters) -Sabre Corp said on Monday it will sell its hospitality software platform to asset manager TPG for $1.1 billion and use the cash to pare its debt, lifting the travel technology provider's shares nearly 26% in early trading. The stock is now...
Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion

3 weeks ago | today.westlaw.com | Sriparna Roy |Alan Barona |Sabrina Valle |Christy Santhosh

(Reuters) - Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 billion, a deal that could give it access to a recently approved rare disease drug and expand its portfolio of...
Bristol Myers' Cobenfy fails in key study as add-on treatment for schizophrenia

3 weeks ago | dagenspharma.dk | Sriparna Roy |Alan Barona

Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration April 22 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly watched late-stage trial that would help expand its use, sending its shares down nearly 5% in after-market trade.
EU authorizes Eisai-Biogen's drug for early Alzheimer's treatment

1 month ago | today.westlaw.com | Sriparna Roy |Alan Barona |Manas Mishra |Shreya Biswas

(Reuters) -The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than two-year-long review process.
Jamie Dimon sells about $31.5 million worth of JPMorgan shares

1 month ago | today.westlaw.com | Nupur Anand |Alan Barona |Jaiveer Shekhawat |Devika Syamnath

(Reuters) -JPMorgan Chase & Co CEO Jamie Dimon has sold about $31.5 million worth of the bank's shares, according to a regulatory filing. Dimon had also offloaded some shares last year in his first such sale since taking over the top role in 2005....
Home improvement retailer Lowe's to buy Artisan Design for $1.33 billion

1 month ago | today.westlaw.com | Savyata Mishra |Alan Barona

(Reuters) -U.S. home improvement retailer Lowe's Cos said on Monday it has agreed to buy Artisan Design Group for $1.33 billion from private equity firm Sterling Group. The deal would help expand Lowe's offering for its professional customers at a...
Japan's Nikkei Slumps on Trade War Worries, Stronger Yen

1 month ago | gurutrade.com | Junko Fujita |Alan Barona |Mrigank Dhaniwala |Eileen Soreng

TOKYO, April 11 (Reuters) - Japan's Nikkei share average slumped on Friday in a brutal end to a volatile week as investors worried about the economic fallout from the rapidly escalating U.S.-China trade war as well as a strong yen that has been lifted by safe-haven flows. The Nikkei ended 2.96% lower at 33,585.58 after declining as much as 5% earlier in the session. The broader Topix closed down 2.85% at 2,466.91. "Risk in equities is too high right now with such huge volatilities every day.
Capital One's $35 billion deal for Discover clears US DOJ hurdle, NYT reports

1 month ago | today.westlaw.com | Alan Barona |Jaiveer Shekhawat

(Reuters) - Capital One Financial Corp got a greenlight from the Justice Department for its proposed acquisition of Discover Financial Services after the DOJ told other regulators looking into the merger that it doesn't see sufficient competition...